{
    "code": "52026656",
    "url": "https:\/\/www.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=52026656",
    "time": "2019-02-15 03:54:56",
    "許可證字號": "衛部藥輸字第026656號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "有效日期": "109\/11\/13",
    "發證日期": "104\/11\/13",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA05202665601",
    "中文品名": "億珂膠囊140毫克",
    "英文品名": "Imbruvica Capsules 140mg",
    "適應症": "1. 被套細胞淋巴瘤\r\nIMBRUVICA 適用於對先前治療無效或復發的被套細胞淋巴瘤Mantle Cell Lymphoma（MCL）成年病人。\r\n\r\n2. 慢性淋巴球性白血病\/小淋巴球性淋巴瘤\r\nIMBRUVICA 適用於治療慢性淋巴球性白血病Chronic Lymphocytic Leukemia（CLL）\/ 小淋巴球性淋巴瘤Small Lymphocytic Lymphoma（SLL）成年病人。\r\n\r\n3.17p缺失性之慢性淋巴球性白血病\/小淋巴球性淋巴瘤\r\nIMBRUVICA適用於治療患有17p缺失性之慢性淋巴球性白血病Chronic Lymphocytic Leukemia（CLL）\/ 小淋巴球性淋巴瘤（SLL）的成年病人。\r\n\r\n4. Waldenström氏巨球蛋白血症\r\nIMBRUVICA適用於治療先前曾接受至少一種治療或於第一線治療時不適合接受化學免疫治療（Chemo-immunotherapy）的Waldenström氏巨球蛋白血症Waldenström’s macroglobulinemia（WM）的成年患者。\r\n\r\n5. 邊緣區淋巴瘤\r\nIMBRUVICA 適用於治療須接受全身性治療且先前曾接受至少一種抗CD20 療法的邊緣區淋巴瘤Marginal Zone Lymphoma（MZL）成年患者。\r\n\r\n6. 慢性移植體抗宿主疾病\r\nIMBRUVICA適用於治療使用一線或多線全身性療法治療失敗後的慢性移植體抗宿主疾病chronic Graft-Versus-Host Disease（cGVHD）成年患者。",
    "劑型": "130膠囊劑",
    "包裝": "8-1000粒塑膠瓶裝(HDPE)",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "06須由醫師處方使用",
    "主成分略述": [
        "Ibrutinib"
    ],
    "限制項目": "02輸　入 1S須執行確認性療效臨床試驗 51免除銜接性臨床試驗",
    "申請商名稱": "1507401100  嬌生股份有限公司",
    "主製造廠": {
        "主製造廠": "",
        "製造廠名稱": "F460774100  CATALENT CTS, LLC",
        "製造廠廠址": "10245 HICKMAN MILLS DRIVE KANSAS CITY, MO 64137, USA",
        "製造廠公司地址": ""
    },
    "CCC號列": "",
    "藥理治療分類": "",
    "次製造廠": [
        {
            "製造廠名稱": "6605071926  久裕企業股份有限公司(委託包裝)",
            "製造廠廠址": "桃園市桃園區大林里興邦路43巷2之1號4樓，3樓B區，1樓A區",
            "製造廠公司地址": "",
            "製造廠國別": "TAIWAN",
            "製程": "貼標廠"
        },
        {
            "製造廠名稱": "F462401000  AndersonBrecon Inc",
            "製造廠廠址": "4545 ASSEMBLY DRIVE, ROCKFORD, IL 61109 USA",
            "製造廠公司地址": "",
            "製造廠國別": "UNITED STATES",
            "製程": "包裝"
        }
    ],
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1013005100",
            "成分名稱": "Ibrutinib",
            "含量描述": "",
            "含量": "140.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "[打樣版](Chi) TW PI_Imbruvica USPI Dec2017 and CCDS 16Aug2016 (MCL3001 result)_v1801_1019-107-12-17.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52026656&Seq=009&Type=9"
        },
        {
            "title": "產品外觀照片-106-03-20(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52026656&Seq=015&Type=8"
        },
        {
            "title": "Imbruvica-shipper label-106-01-05.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52026656&Seq=014&Type=8"
        }
    ]
}